- Featured Product
- KD/KO Validated
c-Met (Cytoplasmic) Antibody
c-Met (Cytoplasmic) Polyclonal Antibody for IHC, IP, WB, ELISA
Cat no : 25869-1-AP
AUTS9, c-Met, HGF receptor, HGF/SF receptor, HGFR, MET, Proto oncogene c Met, RCCP2, Scatter factor receptor, SF receptor, Tyrosine protein kinase Met
|Positive WB detected in||A431 cells, HepG2 cells|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human breast cancer tissue, human colon tissue, human liver cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:200-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
The immunogen of 25869-1-AP is c-Met (Cytoplasmic) Fusion Protein expressed in E. coli.
|Cited Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||c-Met (Cytoplasmic) fusion protein Ag23140|
|Full Name||met proto-oncogene (hepatocyte growth factor receptor)|
|Calculated molecular weight||1390 aa, 155 kDa|
|Observed molecular weight||145 kDa|
|GenBank accession number||BC130420|
|Gene ID (NCBI)||4233|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). The c-met receptor is a 190-kD glycoprotein consisting of a 145-kD membrane-spanning beta chain and a 50-kD alpha chain (PMID: 7806559). In Western blot, this antibody produces bands of unknown identity at 55 and 100 kDa.
|Product Specific Protocols|
|WB protocol for c-Met (Cytoplasmic) antibody 25869-1-AP||Download protocol|
|IHC protocol for c-Met (Cytoplasmic) antibody 25869-1-AP||Download protocol|
|IP protocol for c-Met (Cytoplasmic) antibody 25869-1-AP||Download protocol|
|Click here to view our Standard Protocols|
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.
Oxid Med Cell Longev
Kaohsiung J Med Sci
Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Invest New Drugs
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.